Gonzalo Botija
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gonzalo Botija has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
María‐Luz Cilleruelo
International Doctoral School Universidad Rey Juan Carlos Madrid Spain
2 shared publicationsPedro Urruzuno
Pediatric Gastroenterology Unit Hospital Universitario 12 de octubre Madrid Spain
2 shared publications- Alejandro Rodríguez-Martínez
Pediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain
1 shared publication Alfonso Barrio
Pediatric Gastroenterology Unit Hospital Universitario Fundación Alcorcón Madrid Spain
1 shared publicationAlfonso Barrio M.
Hospital Universitario Fundación Alcorcón
1 shared publication- Alfonso Solar-Boga
Pediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Pediatrics, A Coruña University Hospital, Area Sanitaria A Coruña-Cee, 15006 A Coruña, Spain
1 shared publication
Latest Publications
- Open Access
- 21 April 2026
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 104 (5) , 504161
Helicobacter pylori infection and duodenogastric reflux
- 21 April 2026
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 104 (5) , 504161
Open AccessHelicobacter pylori infection and duodenogastric reflux
- Open Access
- 20 February 2026
- Published by Elsevier in Anales de Pediatría
Infección por Helicobacter pylori y reflujo duodenogástrico
- 20 February 2026
- Published by Elsevier in Anales de Pediatría
Open AccessInfección por Helicobacter pylori y reflujo duodenogástrico
- 19 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 514-522
Evolution of antibiotic resistance pattern of Helicobacter pylori in Spanish children: A 10‐year multicenter study
Objectives: To delineate the evolution of antibiotic resistance over the past decade in Spanish children diagnosed with Helicobacter pylori ( H. pylori ) infection. Methods: An observational, retrospective, multicenter study was conducted in Madrid, Spain. This study included children diagnosed with H. pylori infection via endoscopy with positive culture and antimicrobial susceptibility testing between 2011 and 2020. Results: A total of 1205 patients (56.7% female) were included in the study. Of these, 18.7% had previously undergone unsuccessful treatment. The resistance to the antibiotics tested was as follows: clarithromycin, 42.9% ( n = 504, [95% confidence interval, CI: 40.1%–45.8%]); metronidazole, 24% ( n = 280, [95% CI: 21.5%–26.5%]); rifampicin, 14.8% ( n = 120, [95% CI: 12.4%–17.4%]); levofloxacin, 5.2% ( n = 58, [95% CI: 3.9%–6.6%]); amoxicillin, 2.6% ( n = 30, [95% CI: 1.7%–3.6%]); and tetracycline, 0.9% ( n = 10, [95% CI: 0.4%–1.6%]). The double resistance rate was 12.2% ( n = 143, [95% CI: 10.4%–14.2%]). During the study period, antibiotic resistance remained relatively stable, with a notable decrease in metronidazole (incidence rate ratio [IRR]: 0.941, [95% CI: 0.898–0.985], p = 0.01) and double resistance (IRR: 0.933, [95% CI: 0.875–0.995], p = 0.03) values. The overall eradication rate was 76.6% ( n = 752, [95% CI: 73.8–79.2%]), which was significantly higher in patients without prior treatment. The temporal progression of eradication rates showed a substantial increase, with an average annual increase of 2.9% (IRR: 1.029, [95% CI: 1.015–1.043], p < 0.001). Conclusions: The prevalence of antibiotic resistance in our setting (Madrid, Spain) was remarkably high and remained stable throughout the study period, except for a notable decline in metronidazole and double resistance.
- 19 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 514-522
Evolution of antibiotic resistance pattern of Helicobacter pylori in Spanish children: A 10‐year multicenter study
Objectives: To delineate the evolution of antibiotic resistance over the past decade in Spanish children diagnosed with Helicobacter pylori ( H. pylori ) infection. Methods: An observational, retrospective, multicenter study was conducted in Madrid, Spain. This study included children diagnosed with H. pylori infection via endoscopy with positive culture and antimicrobial susceptibility testing between 2011 and 2020. Results: A total of 1205 patients (56.7% female) were included in the study. Of these, 18.7% had previously undergone unsuccessful treatment. The resistance to the antibiotics tested was as follows: clarithromycin, 42.9% ( n = 504, [95% confidence interval, CI: 40.1%–45.8%]); metronidazole, 24% ( n = 280, [95% CI: 21.5%–26.5%]); rifampicin, 14.8% ( n = 120, [95% CI: 12.4%–17.4%]); levofloxacin, 5.2% ( n = 58, [95% CI: 3.9%–6.6%]); amoxicillin, 2.6% ( n = 30, [95% CI: 1.7%–3.6%]); and tetracycline, 0.9% ( n = 10, [95% CI: 0.4%–1.6%]). The double resistance rate was 12.2% ( n = 143, [95% CI: 10.4%–14.2%]). During the study period, antibiotic resistance remained relatively stable, with a notable decrease in metronidazole (incidence rate ratio [IRR]: 0.941, [95% CI: 0.898–0.985], p = 0.01) and double resistance (IRR: 0.933, [95% CI: 0.875–0.995], p = 0.03) values. The overall eradication rate was 76.6% ( n = 752, [95% CI: 73.8–79.2%]), which was significantly higher in patients without prior treatment. The temporal progression of eradication rates showed a substantial increase, with an average annual increase of 2.9% (IRR: 1.029, [95% CI: 1.015–1.043], p < 0.001). Conclusions: The prevalence of antibiotic resistance in our setting (Madrid, Spain) was remarkably high and remained stable throughout the study period, except for a notable decline in metronidazole and double resistance.
- 1 September 2024
- Published by Wiley in Helicobacter
- Vol. 29 (5) , e13142
Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry
Objectives: To evaluate the efficacy of colloidal bismuth subcitrate (CBS) therapy for the eradication of H. pylori in patients from a national pediatric registry of H. pylori infection.Methods: The Spanish Registry of Children with H. pylori Infection (RENIHp) is a national, multi‐center, prospective, non‐interventional registry that includes children aged 5–18 years with H. pylori infection diagnosed by endoscopy. All patients in the registry who were treated with CBS between the period 2020 and 2023 were included in this study. The primary outcome was the eradication rate, which was assessed using a 13C‐urea breath test or monoclonal antigen in the stool 6–8 weeks post‐treatment.Results: The registry included 682 patients, 38 (5.6%) of whom underwent treatment with CBS. Fifty percent (19/38) of patients had previously undergone unsuccessful eradication treatment. In 78.9% (30/38) of patients, treatment was guided by an antibiotic sensitivity test. In the remaining patients, an empirical approach was employed. The CBS therapies used were as follows: quadruple therapy with proton pump inhibitors (PPIs), CBS, amoxicillin, and metronidazole (MET) [18/38 (47.3%)]; quadruple therapy with PPIs, CBS, tetracycline, and MET [13/38 (34.2%)]; and other therapies [7/38 (18.4%)]. Thirty‐two patients (84.2%) treated with CBS were followed‐up with eradication monitoring. The overall eradication rate in patients treated with CBS was 93.8% (30/32, [95% CI: 85.4%–100%]), whereas it was 86.7% in patients in the registry who were not on CBS treatment (430/496, [95% CI: 83.3%–89.5%], p = 0.208). In the six patients with dual resistance to clarithromycin (CLA) and MET who were treated with quadruple therapy with CBS, the eradication rate was 100% (n = 6/6, [95% CI: 61.0%–100%]).Conclusion: CBS therapies in our registry, although only used in selected cases and at lower than recommended levels, were very effective and showed an eradication rate of > 90%.
- 1 September 2024
- Published by Wiley in Helicobacter
- Vol. 29 (5) , e13142
Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children—Data From the RENIHp Registry
Objectives: To evaluate the efficacy of colloidal bismuth subcitrate (CBS) therapy for the eradication of H. pylori in patients from a national pediatric registry of H. pylori infection.Methods: The Spanish Registry of Children with H. pylori Infection (RENIHp) is a national, multi‐center, prospective, non‐interventional registry that includes children aged 5–18 years with H. pylori infection diagnosed by endoscopy. All patients in the registry who were treated with CBS between the period 2020 and 2023 were included in this study. The primary outcome was the eradication rate, which was assessed using a 13C‐urea breath test or monoclonal antigen in the stool 6–8 weeks post‐treatment.Results: The registry included 682 patients, 38 (5.6%) of whom underwent treatment with CBS. Fifty percent (19/38) of patients had previously undergone unsuccessful eradication treatment. In 78.9% (30/38) of patients, treatment was guided by an antibiotic sensitivity test. In the remaining patients, an empirical approach was employed. The CBS therapies used were as follows: quadruple therapy with proton pump inhibitors (PPIs), CBS, amoxicillin, and metronidazole (MET) [18/38 (47.3%)]; quadruple therapy with PPIs, CBS, tetracycline, and MET [13/38 (34.2%)]; and other therapies [7/38 (18.4%)]. Thirty‐two patients (84.2%) treated with CBS were followed‐up with eradication monitoring. The overall eradication rate in patients treated with CBS was 93.8% (30/32, [95% CI: 85.4%–100%]), whereas it was 86.7% in patients in the registry who were not on CBS treatment (430/496, [95% CI: 83.3%–89.5%], p = 0.208). In the six patients with dual resistance to clarithromycin (CLA) and MET who were treated with quadruple therapy with CBS, the eradication rate was 100% (n = 6/6, [95% CI: 61.0%–100%]).Conclusion: CBS therapies in our registry, although only used in selected cases and at lower than recommended levels, were very effective and showed an eradication rate of > 90%.
- 14 February 2022
- Published by Sociedad Chilena de Pediatria in Andes Pediatrica
- Vol. 93 (1) , 86-92
Síndrome de ACNES, explorando la pared abdominal como noxa del dolor abdominal
El dolor de pared abdominal, y concretamente el síndrome de ACNES (Anterior Cutaneous Nerve Entrapment Syndrome), forma parte del diagnóstico diferencial del dolor abdominal crónico. Este síndrome es poco conocido y por consiguiente infradiagnosticado. Objetivos: Describir las características clínicas y evolutivas de pacientes diagnosticados de ACNES y llamar la atención sobre esta patología. Pacientes y Método: Estudio descriptivo retrospectivo realizado en un centro de referencia, entre octubre 2016 y julio de 2021, en pacientes menores 17 años, diagnosticados de ACNES, que cumpliesen al menos dos de cuatro hallazgos siguientes: signo de Carnett, Pinch test, disestesias en el punto de máximo dolor, mejoría tras infiltración de anestésico local, habiéndose descartado patología abdominal visceral o funcional. Se recogieron variables epidemiológicas, síntomas, exploración física, pruebas complementarias, tratamiento y evolución. Se usaron estadísticas descriptivas. Resultados: 20 pacientes diagnosticados de ACNES, 75% mujeres, mediana de edad 12,85 años. Se objetivó signo de Carnett en 95%, signo de Pinch test en 65% y disestesias en 90% de los pacientes. 65% refirió síntomas pseudoviscerales. 7 pacientes presentaron sobrepeso u obesidad. La localización más frecuente (50%) fue la fosa ilíaca derecha, a nivel T10-T11. Un paciente refirió mejoría espontánea; 7 mejoraron con analgesia oral; 9 fueron derivados a la Unidad del Dolor, de los cuales acudieron 5, los que mejoraron con infiltración anestésica con bupivacaína-triamcinolona; los 4 restantes perdieron seguimiento. Conclusión: El ACNES debe ser considerado en pacientes con dolor abdominal crónico. La combinación de hallazgos típicos en la historia y el examen físico permiten su diagnóstico, evitando pruebas complementarias innecesarias. El tratamiento debe ser escalonado, comenzando por analgesia oral, seguido de infiltración anestésica y, por último, neurectomía anterior.
- 14 February 2022
- Published by Sociedad Chilena de Pediatria in Andes Pediatrica
- Vol. 93 (1) , 86-92
Síndrome de ACNES, explorando la pared abdominal como noxa del dolor abdominal
El dolor de pared abdominal, y concretamente el síndrome de ACNES (Anterior Cutaneous Nerve Entrapment Syndrome), forma parte del diagnóstico diferencial del dolor abdominal crónico. Este síndrome es poco conocido y por consiguiente infradiagnosticado. Objetivos: Describir las características clínicas y evolutivas de pacientes diagnosticados de ACNES y llamar la atención sobre esta patología. Pacientes y Método: Estudio descriptivo retrospectivo realizado en un centro de referencia, entre octubre 2016 y julio de 2021, en pacientes menores 17 años, diagnosticados de ACNES, que cumpliesen al menos dos de cuatro hallazgos siguientes: signo de Carnett, Pinch test, disestesias en el punto de máximo dolor, mejoría tras infiltración de anestésico local, habiéndose descartado patología abdominal visceral o funcional. Se recogieron variables epidemiológicas, síntomas, exploración física, pruebas complementarias, tratamiento y evolución. Se usaron estadísticas descriptivas. Resultados: 20 pacientes diagnosticados de ACNES, 75% mujeres, mediana de edad 12,85 años. Se objetivó signo de Carnett en 95%, signo de Pinch test en 65% y disestesias en 90% de los pacientes. 65% refirió síntomas pseudoviscerales. 7 pacientes presentaron sobrepeso u obesidad. La localización más frecuente (50%) fue la fosa ilíaca derecha, a nivel T10-T11. Un paciente refirió mejoría espontánea; 7 mejoraron con analgesia oral; 9 fueron derivados a la Unidad del Dolor, de los cuales acudieron 5, los que mejoraron con infiltración anestésica con bupivacaína-triamcinolona; los 4 restantes perdieron seguimiento. Conclusión: El ACNES debe ser considerado en pacientes con dolor abdominal crónico. La combinación de hallazgos típicos en la historia y el examen físico permiten su diagnóstico, evitando pruebas complementarias innecesarias. El tratamiento debe ser escalonado, comenzando por analgesia oral, seguido de infiltración anestésica y, por último, neurectomía anterior.
- Open Access
Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP
Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (μg/g) decreased significantly after EEN (830 [IQR 500–1800] to 256 [IQR 120–585] p < 0.0001). Patients with wPCDAI ≤ 57.5, FC < 500 μg/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activity.
Open AccessPredictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP
Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (μg/g) decreased significantly after EEN (830 [IQR 500–1800] to 256 [IQR 120–585] p < 0.0001). Patients with wPCDAI ≤ 57.5, FC < 500 μg/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activity.
- 1 September 2010
- Published by Frontiers Media SA in Transplant International
- Vol. 23 (10) , 1033-1037
Autoimmune cytopaenia after paediatric intestinal transplantation: a case series
Autoimmune cytopaenia is a rare, but severe complication after solid organ transplantation. We retrospectively analysed 57 paediatric intestinal transplants performed in 49 patients between 1999 and 2009. Autoimmune cytopaenia was observed in six patients; it appeared after an average of 10 months post-transplant. Warm autoimmune haemolytic anaemia was developed in three patients, cold autoimmune haemolytic anaemia in one and two presented a mixed type. Incidence and causes for haematological cytopaenia such as the following were investigated: immunosuppression, major blood mismatch, viral infection, malignancy, passenger lymphocyte syndrome and lymphoproliferative disorders. Initial treatment included high-dose steroids, intravenous immunoglobulin, plasmapheresis and maintenance of body temperature above 37°C in those with cold autoantibodies. Inclusion of the spleen in multivisceral transplants seems to be an important risk factor. All patients, except one, relapsed after classic therapy, requiring additional treatments. Sirolimus conversion was performed in four patients. One died after infection. The immunosuppressive therapies associated with other concomitant factors, such as viral infections, lymphoproliferative disorders, graft-versus-host disease, passenger lymphocyte syndrome and the inclusion of the spleen as part of multivisceral graft seem to play an important part in the development of autoimmune processes after intestinal transplantation. Therapy is not well established, especially in those resistant to first-line treatment.
- 1 September 2010
- Published by Frontiers Media SA in Transplant International
- Vol. 23 (10) , 1033-1037
Autoimmune cytopaenia after paediatric intestinal transplantation: a case series
Autoimmune cytopaenia is a rare, but severe complication after solid organ transplantation. We retrospectively analysed 57 paediatric intestinal transplants performed in 49 patients between 1999 and 2009. Autoimmune cytopaenia was observed in six patients; it appeared after an average of 10 months post-transplant. Warm autoimmune haemolytic anaemia was developed in three patients, cold autoimmune haemolytic anaemia in one and two presented a mixed type. Incidence and causes for haematological cytopaenia such as the following were investigated: immunosuppression, major blood mismatch, viral infection, malignancy, passenger lymphocyte syndrome and lymphoproliferative disorders. Initial treatment included high-dose steroids, intravenous immunoglobulin, plasmapheresis and maintenance of body temperature above 37°C in those with cold autoantibodies. Inclusion of the spleen in multivisceral transplants seems to be an important risk factor. All patients, except one, relapsed after classic therapy, requiring additional treatments. Sirolimus conversion was performed in four patients. One died after infection. The immunosuppressive therapies associated with other concomitant factors, such as viral infections, lymphoproliferative disorders, graft-versus-host disease, passenger lymphocyte syndrome and the inclusion of the spleen as part of multivisceral graft seem to play an important part in the development of autoimmune processes after intestinal transplantation. Therapy is not well established, especially in those resistant to first-line treatment.